[The clinical significance of the Philadelphia chromosome in acute leukaemia (author's transl)].
So-called "Philadelphia-positive acute leukaemias" require varied therapeutic management. Additional chromosome anomalies together with Ph1 indicate an acute transformation of a Philadelphia-positive disease, requiring "non-myelotoxic" treatment and new therapeutic approaches. By contrast, "de novo" acute leukaemias with a Ph1-positive karyotype should be treated with intensive chemotherapy for the induction and maintainance of remission.
D000208:Acute Disease; D000328:Adult; D001803:Blood Transfusion; D002904:Chromosomes, Human, 21-22 and Y; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006412:Hematopoietic Stem Cells / Q000648:ultrastructure; D006801:Humans; D007937:Leukapheresis; D007938:Leukemia / Q000235:genetics*; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014750:Vincristine / Q000627:therapeutic use
D005938:Glucocorticoids; D003561:Cytarabine; D014750:Vincristine
Klinische Bedeutung eines Philadelphia-Chromosoms bei akuter Leukämie.